• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Dossier.org

Market Intelligence

  • Sponsored Post
    • Make a Contribution
  • Market Dossier
  • Domain Dossier
  • About
  • Contact

Abingworth Raises $315m for ABV VII 12th Life Sciences Fund

July 9, 2018 By admin Leave a Comment

Abingworth, the international investment group dedicated to life sciences, today announced the final closing of its latest fund, Abingworth Bioventures VII (ABV VII) at $315 million. ABV VII exceeded its target of $300 million and is Abingworth’s 12th fund, investing in life sciences companies in Europe and the US. The firm has funds under management of over $1.2 billion.

The fund invests broadly across all stages of development including early and late-stage venture deals, Clinical Co-development, VIPEs (Venture Investments in Public Equities) and public equities. Investment size per company will typically range from $15 million to $30 million.

“We are delighted to have raised this new fund and to be supported by such high-quality existing and new investors,” said Tim Haines, Managing Partner. “This is an exciting time in medical and scientific innovation to launch our new fund and we look forward to building on our recent achievements.”

Recent exits include the acquisitions of Wilson Therapeutics by Alexion and of IFM Therapeutics by Bristol-Myers Squibb. Abingworth’s funds have also benefited from the rapid progress made by companies such as CRISPR Therapeutics (NASDAQ: CRSP) since investing in the Series A, as well as from GammaDelta Therapeutics, which was seeded by Abingworth and incubated in its London office. In addition, its Clinical Co-Development portfolio has driven significant value with Avillion’s approval of BOSULIF® and SFJ Pharmaceuticals’ approvals of MYLOTARG® and BESPONSA®.

“We believe that Abingworth’s transatlantic presence has contributed significantly to our successful life sciences strategy,” said Kurt von Emster, Managing Partner. “It has increased deal flow and expanded access to markets as well as broadened our network of entrepreneurs, management and investors.”

Abingworth’s investor base has further diversified for ABV VII, including capital from endowments, foundations, fund-of-funds, family offices, healthcare corporations, insurance companies and pension plans across the US, Europe and Asia.

Related

Filed Under: Briefing

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Analysis

Modern business models prove more resilient than legacy business models
Fiverr Opens New Vertical Focused on Data Related Services
Global Pandemic Accelerates Digital Transformation According to Latest Study from Dell Technologies
Trade Show Calendar
Wild Alaska Pollock Is Among the Most Climate-Friendly Proteins in the World
Comparing the Current Crisis and the 2008 Crisis
The Next Oil Boom Is Coming–and It Could Be the Last

Press Media Release

PUBLIC SERVICES INTERNATIONAL LAUNCHES INTERACTIVE DOCUMENTARY EXPERIENCE ON GLOBAL HEALTH WORKERS
Pride Parade 2021
Secretary Blinken’s Call with Polish Foreign Minister Rau
American Association of Nurse Practitioners Applauds Approval of COVID-19 Vaccine; Urges Public to Get Vaccinated
Woolpert Fully Reopens Offices in North America; Employees Offered Flexible Schedules
VOICE Global 2021
HR Maven Tom Painter Joins System High as Vice President of Human Capital

Secondary Sidebar

Opinion

IRGC Quds Force commander from Unit 840 has “fell from his roof”
Kabul airport this morning
Lavrov, Listen This Carefully
it’s a mistake to appease dictators who invade their neighbors
ICYMI: Rubio: A Century of Misery for the Chinese Communist Party

Calendarial

Paris Fintech Forum PFF21, October 13-13, 2021
Connect 2022 London is underway!
Bermuda Climate Summit, May 23-24, 2022
Itron Inspire 2022, September 23-30, 2022, JW Marriott Island Beach Resort, Marco Island, FL
Today is World Refugee Day 2022, Monday, 20 June

Footer

Recent Posts

  • There is a progress in discussions on a potential price cap on Russian oil
  • In 2019 98.9% of EU businesses forming part of the non-financial business economy were micro or small enterprises
  • Microvast Joins Russell 3000® Index
  • EVgo Added to Russell 3000® and Russell 2000® Indexes
  • These techniques boost the effectiveness and efficiency of interactions
  • Orpheus, by McKinsey, named global leader in procurement analytics by industry analysts, attaining top spot in Spend Matters reviews
  • McDonald’s: a real estate firm dressed up as a fast food chain
  • Global cross-border activity to grow 5.6% through 2026
  • Is another housing crash on the horizon?
  • DFIN Report Predicts Strong M&A Activity in 2022

Media Partners

  • Briefly
  • OPINT
  • VPNW
  • S3H
  • Domain Aftermarkets
  • App Coding
  • API Coding
  • Pixel Effect
  • Blockchaining

Media Partners

  • Technology Conferences
  • Event Sharing Network
  • Exclusive
  • Opinion
  • OSINT
  • Domain Name for Business
  • Analysis
  • Digital market
  • Calendarial

Copyright © 2013 Dossier.org

Technologies, Market Analysis & Market Research Reports

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT